• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24845 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2020     Malaysian Health Technology Assessment (MaHTAS) Prophylactic anticoagulation in ambulatory cancer patients
2000     Centre for Clinical Effectiveness (CCE) Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events
2000     Centre for Clinical Effectiveness (CCE) Prophylactic beta-adrenergic blocking agents given perioperatively for preventing post-operative cardiac adverse events
2015     The Regional Health Technology Assessment Centre (HTA-centrum) Prophylactic insertion of a gastrostomy for nutritional support in patients with head and neck cancer
2015     NIHR Health Technology Assessment programme Prophylactic intra-abdominal drains for colorectal surgery
2019     NIHR Health Technology Assessment programme Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT
2002     HAYES, Inc. Prophylactic mastectomy
2002     HAYES, Inc. Prophylactic oophorectomy
2013     HAYES, Inc. Prophylactic oophorectomy for the prevention of ovarian cancer
2019     European Network for Health Technology Assessment (EUnetHTA) Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)
1998     University of York Prophylactic removal of impacted third molars: is it justified?
2012     Belgian Health Care Knowledge Centre (KCE) Prophylactic removal of pathology-free wisdom teeth: rapid assessment
2003     Norwegian Knowledge Centre for the Health Services (NOKC) Prophylactic removal of wisdom teeth
1996     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Prophylactic sclerotherapy of oesophageal varices - primary research
1992     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Prophylaxis of infectious endocarditis - consensus conference
2010     HAYES, Inc. Propofol for moderate sedation during colonoscopy
2005     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Proposal for criteria of public coverage and prioritisation in assisted human reproduction
2002     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Proposal for the indication of PET in oncology with public coverage in Catalonia
2006     Health Council of the Netherlands Gezondheidsraad (GR) Proposals for research into health effects of electromagnetic fields (0Hz - 300 GHZ)
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Proposed delay for safe surgery after COVID-19
2017     Adelaide Health Technology Assessment (AHTA) Prosigna (PAM50) for predicting breast cancer recurrence
2014     HAYES, Inc. Prosigna breast cancer prognostic gene signature assay
2015     HAYES, Inc. Prosigna Breast Cancer Prognostic Gene Signature Assay
2019     Norwegian Institute of Public Health (NIPH) Prosigna Gene Signature to Assess Expected Benefit from Chemotherapy in Breast Cancer. Assessment of manufacturer’s submission
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Prosorba (R) blood filtration column
2001     Alberta Heritage Foundation for Medical Research (AHFMR) Prosorba treatment for rheumatoid arthritis
2014     NIHR Health Technology Assessment programme Prospective multicentre randomised, double-blind, equivalence study comparing clonidine and midazolam as intravenous sedative agents in critically ill children: the SLEEPS (Safety profiLe, Efficacy and Equivalence in Paediatric intensive care Sedation) study
2021     NIHR Health Technology Assessment programme Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation
2003     Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ) Prospective study into the influence of high-dose chemotherapy with adjuvant treatment with peripheral stem cells on the disease-free survival of patients with mammary carcinoma and four or more metastatic lymph glands in the armpit - primary research
2005     Institute for Clinical Effectiveness and Health Policy (IECS) Prostacyclins (epoprostenol, iloprost, treprostinil and beraprost) for the management of primary pulmonary hypertension and pulmonary hypertension in collagen vascular disease
2009     Institute for Clinical Effectiveness and Health Policy (IECS) Prostacyclins (epoprostenol, iloprost, treprostinil and beraprost) for the management of primary pulmonary hypertension and pulmonary hypertension in collagen vascular disease
2007     Canadian Agency for Drugs and Technologies in Health (CADTH) Prostaglandin analogues for ophthalmic use: analysis of clinical and cost-effectiveness
2001     HAYES, Inc. Prostascint
2017     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Prostate artery embolisation for benign prostatic hyperplasia
2017     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Prostate artery embolisation for benign prostatic hyperplasia
2018     National Institute for Health and Care Excellence (NICE) Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 611
2018     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Prostate artery embolisation: poor design and reporting impact the value of current systematic reviews
2016     Institute for Clinical Effectiveness and Health Policy (IECS) Prostate bipolar transurethral resection for the treatment of benign prostatic hyperplasia
2006     NIHR Horizon Scanning Centre (NIHR HSC) Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer: horizon scanning technology briefing
2017     Health Quality Ontario (HQO) Prostate cancer patient perspectives on the use of information in treatment decision-making: a systematic review and qualitative meta-synthesis
2011     Health Technology Assessment Section, Ministry of Health Malaysia (MaHTAS) Prostate cancer screening
1996     Australian Health Technology Advisory Committee (AHTAC) Prostate cancer screening (consumer statement)
1996     Australian Health Technology Advisory Committee (AHTAC) Prostate cancer screening (executive summary)
1996     Australian Health Technology Advisory Committee (AHTAC) Prostate cancer screening (technical report)
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Prostate cancer screening: a review of the guidelines
1999     Basque Office for Health Technology Assessment (OSTEBA) Prostate cancer screening: evidence synthesis and update (INAHTA Joint Project)
2004     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) Prostate Oncoguide
2010     HAYES, Inc. Prostate Px (Aureon Laboratories Inc.) for prediction of recurrence of prostate cancer
2006     HAYES, Inc. Prostate saturation biopsy for diagnosis of prostate cancer
2005     Medical Services Advisory Committee (MSAC) Prostate specific antigen (PSA) near patient testing for diagnosis and management of prostate cancer
1995     Health Services Utilization and Research Commission (HSURC) Prostate specific antigen (PSA) testing
2003     NIHR Health Technology Assessment programme Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
1999     NIHR Health Technology Assessment programme Prostate trials office (PROTO): co-ordinating trials of new technologies in the treatment of BPH
2009     NIHR Health Technology Assessment programme Prostate trials office (PROTO): co-ordinating trials of new technologies in the treatment of BPH
2002     Institute for Clinical Evaluative Sciences (ICES) Prostate-specific antigen (PSA) screening in asymptomatic men
2015     Health Quality Ontario (HQO) Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an economic analysis
2015     Health Quality Ontario (HQO) Prostate-Specific Antigen (PSA)–based population screening for prostate cancer: an evidence-based analysis
2002     HAYES, Inc. Prostate-specific antigen testing for prognosis and monitoring of patients with prostate cancer
2003     HAYES, Inc. Prostate-specific antigen testing for screening and early detection of prostate cancer
2006     Belgian Health Care Knowledge Centre (KCE) Prostate-specific-antigen (PSA) for the screening of prostate cancer
2021     Ontario Health Prostatic artery embolization for benign prostatic hyperplasia
1992     Danish Institute for Health Services Research (DSI) Prostatic cancer in the Nordic Countries
2022     National Institute for Health and Care Excellence (NICE) Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 737
2008     Agenzia nazionale per i servizi sanitari regionali (Agenas) Prostheses for primary total hip replacement in Italy
2009     Agenzia nazionale per i servizi sanitari regionali (Agenas) Prostheses for primary total knee replacement in Italy
2012     The Regional Health Technology Assessment Centre (HTA-centrum) Prosthetic arthroplasty in primary shoulder osteoarthritis
1994     University HealthSystem Consortium (UHC) Prosthetic hip and knee arthroplasty
2006     Institute for Clinical Effectiveness and Health Policy (IECS) Prosthetic intervertebral disc replacement
2010     National Institute for Health and Care Excellence (NICE) Prosthetic intervertebral disc replacement in the cervical spine. NICE interventional procedures guidance 341
2009     National Institute for Health and Care Excellence (NICE) Prosthetic intervertebral disc replacement in the lumbar spine. NICE interventional procedures guidance 306
2010     The Swedish Council on Health Technology Assessment (SBU) Prosthetic rehabilitation of partially dentate or edentulous patients
2013     NIHR Horizon Scanning Centre (NIHR HSC) PROSTVAC Immunotherapy for chemotherapy-naïve hormone-relapsed prostate cancer
2013     Canadian Agency for Drugs and Technologies in Health (CADTH) Protease inhibitor use for chronic hepatitis C infection in prior null responders and recurrent hepatitis C infection post liver transplant: a review of the clinical evidence
2012     Canadian Agency for Drugs and Technologies in Health (CADTH) Protease inhibitor use for chronic hepatitis C infection in special populations: a review of the clinical evidence and guidelines
1996     Health Council of the Netherlands Gezondheidsraad (GR) Protection against diphtheria
1996     Health Council of the Netherlands Gezondheidsraad (GR) Protection against Hepatitis B
2015     Canadian Agency for Drugs and Technologies in Health (CADTH) Protein testing in patients with multiple myeloma: a review of clinical effectiveness and guidelines
2008     HAYES, Inc. Prothrombin G20210A for risk assessment for venous thromboembolism (VTE) or obstetric complications
2025     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of immunisation against respiratory syncytial virus in Ireland
2026     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of modifications to the BreastCheck programme. Workstream 1 (of 2): consideration of screening pathways that incorporate breast density
2024     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of screening for abdominal aortic aneurysm in men
2025     Health Information and Quality Authority (HIQA) Protocol for a health technology assessment of teledermatology to support the management of primary care referrals
2026     Health Information and Quality Authority (HIQA) Protocol for a systematic review on the association between alcohol consumption and mental health outcomes
2025     NIHR Health Technology Assessment programme Protocol for DexEnceph: a randomised controlled trial of dexamethasone therapy in adults with herpes simplex virus encephalitis
2026     Health Information and Quality Authority (HIQA) Protocol for modelling the risk of alcohol-attributable mortality and hospital admission in Ireland
2008     Quality Improvement Scotland (NHS QIS ) Protocol for systematic review on provision of patient information
2026     Health Information and Quality Authority (HIQA) Protocol for the health technology assessment of the introduction of population-based screening for familial hypercholesterolaemia in children
2025     Health Information and Quality Authority (HIQA) Protocol: development of a tool for the collection of costs attributable to infectious disease outbreaks in public acute hospitals
2015     NIHR Health Technology Assessment programme Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock
2019     NIHR Health Technology Assessment programme Protocolised non-invasive compared with invasive weaning from mechanical ventilation for adults in intensive care: the Breathe RCT
2017     Penn Medicine Center for Evidence-based Practice (CEP) Protocols for discontinuing the use of 1:1 patient sitters in the acute care setting
2005     Institute of Health Economics (IHE) Protocols for stillbirth investigation
2005     Alberta Heritage Foundation for Medical Research (AHFMR) Protocols for stillbirth investigation
2020     Austrian Institute for Health Technology Assessment (AIHTA) Proton and carbon ion therapy - an update on indications
1998     ECRI Proton beam radiation therapy for prostate cancer
2004     HAYES, Inc. Proton beam therapy
2014     Institute for Clinical and Economic Review (ICER) Proton beam therapy
2010     VA Technology Assessment Program (VATAP) Proton beam therapy for cancer
2021     Ontario Health Proton Beam Therapy for Cancer in Children and Adults: A Health Technology Assessment
2017     HAYES, Inc. Proton beam therapy for non-small cell lung cancer